Inovio Pharmaceuticals, Inc. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; balance-sheet comparisons are with December 31, 2011. The unaudited statements are prepared on a going-concern basis. Inovio is a clinical-stage biotechnology company developing DNA vaccines and electroporation delivery technology; it had no approved human products and no product-sale revenue.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 or prior date |
|---|---|---|
| Total revenue | $1.69 million | $3.11 million |
| Operating loss | $4.19 million | $4.39 million |
| Net loss | $8.26 million | $2.42 million |
| Net loss per share, basic and diluted | $0.06 | $0.02 |
| Net cash used in operating activities | $5.44 million | $5.50 million |
| Cash and cash equivalents | $11.13 million | $17.35 million at Dec. 31, 2011 |
| Short-term investments | $13.73 million | $12.86 million at Dec. 31, 2011 |
| Working capital | $13.9 million | $20.9 million at Dec. 31, 2011 |
- Revenue fell 45% year over year, principally because less NIAID contract work was performed and recognized in the quarter. Grant and miscellaneous revenue was $1.56 million versus $2.99 million; license and milestone revenue was $131,000 versus $120,000.
- R&D expense declined to $4.04 million from $4.42 million; general and administrative expense declined to $2.49 million from $3.32 million. Operating loss narrowed modestly. The filing does not present a gross margin measure.
- Net loss widened largely because the company recorded a $3.55 million expense from the change in fair value of its own common-stock warrants, compared with a $2.33 million gain in Q1 2011. The warrant liability rose to $8.42 million from $5.18 million at year-end. These are fair-value accounting changes, not operating cash outflows.
- Cash used in investing activities was $784,000; there was no financing cash flow in Q1 2012. Cash and cash equivalents declined by $6.22 million during the quarter.
- Total liabilities were $15.12 million, including the $8.42 million warrant liability and deferred revenue. The balance sheet does not list conventional borrowings or debt.
Material changes and notable items
- Revenue from the NIAID HIV-vaccine contract was $1.5 million, compared with $2.7 million in Q1 2011, reflecting timing of work performed. The contract had approved five-year funding of $23.0 million, with two option years that could bring total potential value to $25.3 million.
- In March 2012, an amendment to the OncoSec asset-sale agreement extended payment timing in exchange for a warrant to purchase 3 million OncoSec shares. Inovio reported $2.5 million of scheduled future payments but recorded no receivable because collection was not reasonably assured. The company also recognized a $501,000 gain on receipt of the warrant, followed by a $307,000 decrease in its fair value during the quarter.
- VGX International was to fund IND-enabling and initial Phase I/II studies for hepatitis B and C vaccine programs in exchange for specified Asian marketing rights. Inovio reported a 16.1% ownership interest in VGX International following its 2011 rights offering.
- Common shares outstanding were 134,968,394 as of May 4, 2012. In addition, 21.7 million company warrants were outstanding at March 31, 2012; options and other potentially dilutive securities were excluded from diluted loss per share as anti-dilutive.
Outlook, risks and management commentary
- Management said the company expected to rely on outside financing to meet capital needs into the third quarter of 2013, was evaluating collaborations, and might never achieve positive cash flow or profitability. The filing does not provide earnings or revenue guidance.
- Management cited a $218.3 million accumulated deficit and expected substantial future operating losses as research, preclinical, clinical and regulatory work continued. The company had working capital of $13.9 million at quarter-end.
- Key risks include the need for additional capital and possible dilution; uncertain clinical results, trial timing and regulatory approval; manufacturing and commercialization challenges; dependence on grants, government contracts and a limited number of partners; and competition, intellectual-property disputes and potential product liability.
- The filing reported that disclosure controls were effective as of March 31, 2012, with no material change in internal control over financial reporting during the quarter. It reported no applicable legal proceedings and no material changes to the risk factors in the 2011 Form 10-K.
Important facts for investors to verify
- Cash runway and financing needs: validate spending trends, access to capital and the assumptions behind management’s stated funding horizon.
- NIAID contract work and funding, including timing of revenue recognition and any option-year funding.
- Clinical and regulatory progress for vaccine candidates, and whether trial and manufacturing plans remain adequately funded.
- Warrant liability valuation assumptions and potential dilution from outstanding warrants, options and any future equity issuance.
- Collectability and timing of OncoSec’s remaining scheduled payments, which were not recorded as a receivable.